CORRECTING and REPLACING PHOTO Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series
Please replace the photo with the accompanying corrected photo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005025/en/
Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series (Photo: Business Wire)
The release reads:
ZYNGA CELEBRATES BUGATTI’S 110TH ANNIVERSARY WITH SPECIAL CSR RACING 2 EVENT SERIES
Players Can Race and Collect Exclusive Bugatti-Engineered Hyper Sports Cars in Game
Today, Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, is launching an event series in partnership with the hyper sports car manufacturer Bugatti in the hit mobile drag racing game, CSR Racing 2 (CSR2). The event series, which celebrates Bugatti’s 110th anniversary, will give players the opportunity to collect and compete with the world’s most powerful and exclusive hyper sports cars in CSR2.
“Bugatti is one of the most iconic and revered car manufacturers in the world, and we are truly honored to celebrate such an important milestone with them,” said Julian Widdows, Vice President of CSR2. “Our team worked tirelessly to make sure everything from the cars’ sleek forms to their powerful engines is authentically represented in the game. This is the closest an aficionado can come to owning a Bugatti without actually buying one.”
The series showcases 24 different Bugatti cars, three of which are available exclusively in CSR2. Players can view the cars in augmented reality, giving them the experience of sitting in the driver’s seats of the most desirable hyper sports cars ever designed. The integration has seven different events over an eight-week period, and will be highlighted in a continued beta version of CSR2’s new player-versus-player feature, Showdown.
CSR2 Bugatti Exclusives:
- Chiron Super Sport 300: the first series production car to break the magical 300 miles per hour barrier
- La Voiture Noire: a one-off one grand tourisme masterpiece
- Centodieci: the newly released homage to the original modern-day super sports car, EB110
“Interactive entertainment is a main driver for today’s young generation’s enthusiasm for cars and a great way to stay in touch with fans around the world,” said Bugatti President, Stephan Winkelmann. “We are very excited that through this partnership, our enthusiasts have the opportunity to experience all of our latest exclusive Bugatti hyper sports cars in CSR2.”
Every aspect of the 24 Bugatti cars, from the grills to the paint color, dashboard finish and stitching, has been meticulously recreated in CSR2 to mirror the real hyper sports cars. Players can explore the cars by tapping special points to trigger handcrafted, bespoke animations, allowing them to open doors, pop the hoods, inspect the engine bays, extend the spoilers and more.
CSR2 is available to download for free on the App Store as well as the Google Play Store. For more information about CSR2, visit the game’s community channels on Facebook, Twitter, Instagram, and YouTube.
Editor’s Note - To view the supporting assets for CSR Racing 2 (CSR2), please click here: https://app.box.com/s/56junq0iv8ibm2dx0mqfo8hpkd7qlk64
About Zynga Inc.
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing™, Empires & Puzzles™, Merge Dragons!™, Words With Friends™ and Zynga Poker™. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter and Facebook.
About Bugatti
Bugatti Automobiles S.A.S. manufactures the world's most powerful, fastest, most exclusive and luxurious production hyper sports car. Since its foundation in 1909, the French luxury brand has been based on and off in Molsheim, Alsace. The Veyron was made there between 2005 and 2015, the first modern-day hyper sports car, of which 450 vehicles were built by hand. Since autumn 2016, the staff in Molsheim have been producing the Chiron1 models.
With an output of 1,500 hp, which has never before been achieved by production vehicles, a torque of 1,600 newton metres at 2,000 to 6,000 rpm and numerous technical innovations, the Chiron1 has been setting new standards in automotive engineering ever since.
In 2017, Bugatti delivered 70 vehicles to customers, by 2018 this had increased to 76. More than 80 vehicles are set to be delivered to customers in 2019. Bugatti has announced the construction of 500 models – currently only 100 Chiron can be ordered. Production of the Divo2, a vehicle optimised for lateral acceleration, will follow soon.
Bugatti has been part of the Volkswagen Group since 1998 and employs more than 300 people. The majority of these work in Molsheim in Alsace. With 37 dealers and service partners in 18 countries in Europe, North America, the Middle East and Asia-Pacific, Bugatti is a global player.
1 Fuel consumption, l/100km: urban 35.2 / extra-urban 15.2 / combined 22.5; combined CO2 emissions, g/km: 516; efficiency class: G
2 Fuel consumption, l/100km: not subject to Directive 1999/94/EC as overall type approval is currently not yet available
Forward Looking Statement
This press release contains forward-looking statements, relating to, among other things, the release of future CSR Racing 2 game features and events. Forward-looking statements often include words such as "outlook," "projected," “planned,” "intends," "will," "anticipate," "believe," "target," "expect," and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained by visiting our Investor Relations web site at http://investor.zynga.com or the SEC's web site at www.sec.gov
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005025/en/
Contact information
Zynga Media Contact:
Kenny Johnston
kjohnston@zynga.com | (602) 999-1890
Or
Bugatti Automobiles S.A.S. Contact:
Tim Bravo
Head of Communications
Mobile: +33 640 151969
Email: tim.bravo@bugatti.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
